A Phase I, Dose-escalation Study of AS703569 Given Orally to Subjects With Haematological Malignancies

Update Il y a 5 ans
Reference: NCT01080664

Woman and Man

Extract

EMD Serono decided to terminate enrollment based on a review of the available clinical data and low probability of completing the trial based on the observed recruitment rate. Subjects already enrolled in the study continued participation in the study, consistent with the protocol, to study completion.


Inclusion criteria

  • haematological malignancies


Links